相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
Caroline Marty et al.
BLOOD (2016)
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
D. Pietra et al.
LEUKEMIA (2016)
Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia
Yoseph C. Elala et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji et al.
BLOOD (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
P. Guglielmelli et al.
BLOOD CANCER JOURNAL (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
A compendium of cytogenetic abnormalities in myelofibrosis: molecular and phenotypic correlates in 826 patients
Emnet Wassie et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution
X. Cabagnols et al.
LEUKEMIA (2015)
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
Giada Rotunno et al.
BLOOD (2014)
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
Elisa Rumi et al.
BLOOD (2014)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants
Ayalew Tefferi et al.
BLOOD (2014)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli et al.
BLOOD (2014)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
Juan-Carlos Hernandez-Boluda et al.
HAEMATOLOGICA (2014)
Calreticulin mutations in Chinese with primary myelofibrosis
Bing Li et al.
HAEMATOLOGICA (2014)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
A. Tefferi et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P. Guglielmelli et al.
LEUKEMIA (2014)
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
A. Tefferi et al.
LEUKEMIA (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
Terra L. Lasho et al.
BLOOD (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
Richard T. Silver et al.
LEUKEMIA RESEARCH (2011)
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
F. Passamonti et al.
LEUKEMIA (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2008)
Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment
G. Barosi et al.
LEUKEMIA (2008)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Alessandro M. Vannucchi et al.
BLOOD (2007)
分享论文
